Opiant Pharmaceuticals — FY2022 Earnings Presentation
19 slides from Opiant Pharmaceuticals's earnings presentation, Feb 16, 2023
Slide 1: Q4/FY 2022 Results
Q4/FY 2022 Results February 16, 2023
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding the Indivior Group’s financial guidance for 2023 and its medium- and long-term growth outlook; expectations for sales levels
Slide 3: Agenda
Agenda Mark Crossley Overview & Strategic Priorities Update Christian Heidbreder R&D Update Ryan Preblick Q4/FY 2022 Performance & FY 2023 Guidance Mark Crossley Conclusion All Q&A
Slide 4: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 5: FY 2022 key messages
FY 2022 key messages ( Continued strong execution in FY 2022 – Total NR1 up 14% driven by SUBLOCADE®; SUBLOCADE NR grew 67% to $408m Pending Opiant Pharmaceuticals transaction anticipated to close early March FY 2023 guidance introduced – expect top-line growth and positive operating leverage, consi
Slide 6: Proactively addressing legacy litigation
Proactively addressing legacy litigation Initial mediation sessions in late January 2023 regarding legacy civil multidistrict antitrust litigation provided the Group with new information on the previously disclosed contingent liability. Accordingly, the Group recorded an exceptional provision of $29
Slide 7: Executing clear strategies for value creation
Executing clear strategies for value creation 4 Optimize Operating Model 1 Grow SUBLOCADE >$1.5bn 2 Diversify Revenue 3 Build & Progress Pipeline Peak NR increased to >$1.5bn (expect >$1bn NR run-rate exiting 2025) FY22 NR of $408m, +67% Ending patients1 of 82.5k, +68%; targeting 270k patients US di
Slide 8: Medium-term profitable growth framework
Medium-term profitable growth framework Attractive Growth Profile Positive Operating Leverage Strengthening Cash Flow
Slide 9: Christian Heidbreder, Chief Scientific Officer
Christian Heidbreder Chief Scientific Officer
Slide 10: SUBLOCADE strategic R&D and medical priorities 2023
SUBLOCADE strategic R&D and medical priorities 2023 Breaking Barriers Label updates Long-term collaborations (e.g., RECOVER, CoLAB , EXPO) Externally Sponsored Studies (ESS) Real World Evidence (RWE) studies Long-term efficacy & safety (LTES) studies Peer-reviewed publications & Conferences Patient
Slide 11: Most recent peer-reviewed publications
Most recent peer-reviewed publications Long‐term recovery from opioid use disorder: recovery subgroups, transition states and their association with substance use, treatment and quality of life - Craft - Addiction - Wiley Online Library Frontiers | Buprenorphine exposure levels to optimize treatment
Slide 12: Regulatory approvals in global markets
Regulatory approvals granted in 11 MoW countries including Canada, Australia, New Zealand, Israel, Sweden, Finland, Denmark, Norway, Germany, Italy and Switzerland Pending approval in the UK Geo-expansion submissions planned in Kuwait, KSA, UAE, and Qatar Regulatory approvals granted in Canada, Isra
Slide 13: Pipeline activities
Characterization of two lead molecules, two additional back-up molecules, and scale-up and manufacture of one lead Finalization of primary and secondary in vivo profiling studies for lead molecules Decision for candidate selection of one lead molecule Q1 2023 Objectives for 2023 are to: Progress non
Slide 14: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 15: FY 2022 financial highlights
FY 2022 financial highlights Takeaways Top-line NR growth of 14% vs. FY 2021 US NR up 21% ROW NR down 10% including FX (up 1% excluding FX) Total SUBLOCADE NR up 67% vs. FY 2021; PERSERIS NR up 65% vs. FY 2021 Reported operating expenses include $290m exceptional legacy antitrust multidistrict litig
Slide 16: Cash & borrowing position
Cash & borrowing position Cash & Borrowing Total gross cash & investments of $991m1: Cash and investments primarily held in USD Approximately $90m used for share repurchases during FY 2022 at an average price of 1,537p Disciplined and consistent capital allocation in FY 22: Deliver against SUBLOCADE
Slide 17: FY 2023 guidance introduced
FY 2023 guidance introduced Excludes impacts from the pending transactions with Opiant Pharmaceuticals Additional Top-Line Assumptions Underlying BMAT market growth of mid- to high-single digits US SUBOXONE Film Anticipated formulary decisions expected to impact share by approximately 2 points, simi
Slide 18: Appendix
Appendix
Slide 19: Financial Reconciliation: FY 2022 & FY 2021
FY 2022 FY 2021 ($ in mil. at Actual FX ) Net Income / (Loss) (53) 205 Net interest (expense) / income 10 23 Taxation (42) (15) Operating Profit / (Loss) (85) 213 Adjustments 297 (26) Adjusted Operating Profit / (Loss) 212 187 Financial Reconciliation: FY 2022 & FY 2021 FY 2022 Notes: $290m impact f
Opiant Pharmaceuticals — FY2022 Earnings Presentation on 6ix